erythrocyte membrane protein band 4.1 like 4BGenealiases: CG1 · EHM2 · LULU2
Q-omics provides the consensus-scored EPB41L4B profile across patient tissues and cancer cell-line models. EPB41L4B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EPB41L4B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, EPB41L4B protein abundance shows 22,660 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where EPB41L4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPB41L4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPB41L4B survival associations across molecular data types. EPB41L4B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPB41L4B RNA expression–survival associations across cancer types. High EPB41L4B expression shows unfavorable associations in KIRC, KIRP, BRCA, ACC, ESCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EPB41L4B RNA expression.
This table summarizes EPB41L4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EPB41L4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPB41L4B shows lower tumor expression in KIRC, COAD, THCA and KIRP and higher tumor expression in HNSC and BLCA. The KIRC box plot shows higher EPB41L4B RNA expression in normal versus tumor tissue (log2 FC = −3.024, t-test p < 0.001).
This table shows molecular features associated with EPB41L4B in patient tissues and cancer cell lines. In patient samples, EPB41L4B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, EPB41L4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
